TransCode TherapeuticsRNAZ +10.69%34 Market Cap is $4.72 Mil as of Jun. 26, 2026. GuruFocus rates RNAZ with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,431 Biotechnology companies, TransCode Therapeutics ranks worse than 91.96% on this metric.
TransCode Therapeutics's quarterly market cap
declined
from Sep. 2025 ($8.97 Mil) to Dec. 2025 ($6.26 Mil) but then
increased
from Dec. 2025 ($6.26 Mil) to Mar. 2026 ($7.90 Mil).
TransCode Therapeutics's annual market cap
declined
from Dec. 2023 ($6.09 Mil) to Dec. 2024 ($3.49 Mil) but then
increased
from Dec. 2024 ($3.49 Mil) to Dec. 2025 ($6.26 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. TransCode Therapeutics's Enterprise Value for Today is $-1.05 Mil.
TransCode Therapeutics (NAS:RNAZ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, TransCode Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransCode Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where TransCode Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
TransCode Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransCode Therapeutics (RNAZ) has a Market Cap of $4.72 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on TransCode Therapeutics and its competitors. According to the industry distribution chart, TransCode Therapeutics ranks #1316 out of 1431 companies in the Biotechnology industry, placing it in the top 92%.
Is TransCode Therapeutics' Market Cap too high?
TransCode Therapeutics' current Market Cap is $4.72 Mil. The Biotechnology industry median Market Cap is 113.83. TransCode Therapeutics' value of $4.72 Mil is 95.9% below this industry median. Based on the distribution chart, TransCode Therapeutics ranks #1316 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TransCode Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' Market Cap compare to ARTL and GLMD?
According to the Biotechnology industry distribution chart, TransCode Therapeutics ranks #1316 out of 1431 companies for Market Cap. This places TransCode Therapeutics in the lower half of its industry. The industry median Market Cap is 113.83. TransCode Therapeutics' value of $4.72 Mil is 95.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransCode Therapeutics's current Market Cap of $4.72 Mil is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on TransCode Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransCode Therapeutics's current Market Cap is $4.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current Market Cap of $4.72 Mil. The current Market Cap is $4.72 Mil and 95.9% below the Biotechnology industry median of 113.83. TransCode Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current Market Cap is $4.72 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
34GF Score
Get the complete analysis for RNAZ
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNAZ has been successfully added to your 
